RU2012149115A - Фармацевтическая композиция - Google Patents
Фармацевтическая композиция Download PDFInfo
- Publication number
- RU2012149115A RU2012149115A RU2012149115/15A RU2012149115A RU2012149115A RU 2012149115 A RU2012149115 A RU 2012149115A RU 2012149115/15 A RU2012149115/15 A RU 2012149115/15A RU 2012149115 A RU2012149115 A RU 2012149115A RU 2012149115 A RU2012149115 A RU 2012149115A
- Authority
- RU
- Russia
- Prior art keywords
- sodium
- surfactant
- cellulose
- composition
- composition according
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 6
- 239000000203 mixture Substances 0.000 claims abstract 33
- 239000004094 surface-active agent Substances 0.000 claims abstract 15
- 239000002245 particle Substances 0.000 claims abstract 12
- 229920000642 polymer Polymers 0.000 claims abstract 12
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims abstract 9
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims abstract 8
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims abstract 8
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims abstract 7
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims abstract 7
- 229960003804 efavirenz Drugs 0.000 claims abstract 7
- 229920002675 Polyoxyl Polymers 0.000 claims abstract 6
- 150000002148 esters Chemical class 0.000 claims abstract 6
- 239000003381 stabilizer Substances 0.000 claims abstract 6
- 150000003871 sulfonates Chemical class 0.000 claims abstract 6
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract 5
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims abstract 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract 4
- 150000002334 glycols Chemical class 0.000 claims abstract 4
- 239000011734 sodium Substances 0.000 claims abstract 4
- 229910052708 sodium Inorganic materials 0.000 claims abstract 4
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims abstract 4
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 claims abstract 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract 3
- IEORSVTYLWZQJQ-UHFFFAOYSA-N 2-(2-nonylphenoxy)ethanol Chemical compound CCCCCCCCCC1=CC=CC=C1OCCO IEORSVTYLWZQJQ-UHFFFAOYSA-N 0.000 claims abstract 3
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract 3
- 239000002202 Polyethylene glycol Chemical class 0.000 claims abstract 3
- 229920001214 Polysorbate 60 Polymers 0.000 claims abstract 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims abstract 3
- 150000001298 alcohols Chemical class 0.000 claims abstract 3
- 150000008051 alkyl sulfates Chemical class 0.000 claims abstract 3
- 239000002280 amphoteric surfactant Substances 0.000 claims abstract 3
- 239000003945 anionic surfactant Substances 0.000 claims abstract 3
- 239000003833 bile salt Substances 0.000 claims abstract 3
- 229940093761 bile salts Drugs 0.000 claims abstract 3
- 150000007942 carboxylates Chemical class 0.000 claims abstract 3
- 239000004359 castor oil Substances 0.000 claims abstract 3
- 235000019438 castor oil Nutrition 0.000 claims abstract 3
- 125000002091 cationic group Chemical group 0.000 claims abstract 3
- 239000003093 cationic surfactant Substances 0.000 claims abstract 3
- 229960003964 deoxycholic acid Drugs 0.000 claims abstract 3
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims abstract 3
- 229960000878 docusate sodium Drugs 0.000 claims abstract 3
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 claims abstract 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract 3
- 235000010445 lecithin Nutrition 0.000 claims abstract 3
- 239000000787 lecithin Substances 0.000 claims abstract 3
- 229940067606 lecithin Drugs 0.000 claims abstract 3
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000002736 nonionic surfactant Substances 0.000 claims abstract 3
- 229920000847 nonoxynol Polymers 0.000 claims abstract 3
- 239000003921 oil Substances 0.000 claims abstract 3
- 239000003208 petroleum Substances 0.000 claims abstract 3
- 229920001223 polyethylene glycol Chemical class 0.000 claims abstract 3
- 229920000136 polysorbate Polymers 0.000 claims abstract 3
- 229940068965 polysorbates Drugs 0.000 claims abstract 3
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims abstract 3
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 claims abstract 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims abstract 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 17
- -1 glycol fatty acid esters Chemical class 0.000 claims 13
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 6
- 229930006000 Sucrose Natural products 0.000 claims 6
- 239000005720 sucrose Substances 0.000 claims 6
- 239000008187 granular material Substances 0.000 claims 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims 4
- 239000000194 fatty acid Substances 0.000 claims 4
- 229930195729 fatty acid Natural products 0.000 claims 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 4
- 238000010521 absorption reaction Methods 0.000 claims 3
- 150000004665 fatty acids Chemical class 0.000 claims 3
- 159000000000 sodium salts Chemical class 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- 229920002774 Maltodextrin Polymers 0.000 claims 2
- 239000005913 Maltodextrin Substances 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 150000003973 alkyl amines Chemical class 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 239000000908 ammonium hydroxide Substances 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 229960000913 crospovidone Drugs 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000007970 homogeneous dispersion Substances 0.000 claims 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 229960001375 lactose Drugs 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 229960001021 lactose monohydrate Drugs 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims 2
- 229940035034 maltodextrin Drugs 0.000 claims 2
- 229920000609 methyl cellulose Polymers 0.000 claims 2
- 239000001923 methylcellulose Substances 0.000 claims 2
- 235000010981 methylcellulose Nutrition 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 229920000058 polyacrylate Polymers 0.000 claims 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 125000000185 sucrose group Chemical group 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- KBLIPMUZOQSCGF-UHFFFAOYSA-N C1(=CC=CC=C1)C.S(O)(O)(=O)=O.Cl Chemical class C1(=CC=CC=C1)C.S(O)(O)(=O)=O.Cl KBLIPMUZOQSCGF-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- SGXDXUYKISDCAZ-UHFFFAOYSA-N N,N-diethylglycine Chemical compound CCN(CC)CC(O)=O SGXDXUYKISDCAZ-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 claims 1
- 229940097362 cyclodextrins Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 238000000227 grinding Methods 0.000 claims 1
- 238000000265 homogenisation Methods 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000008297 liquid dosage form Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 229940066765 systemic antihistamines substituted ethylene diamines Drugs 0.000 claims 1
- 150000001733 carboxylic acid esters Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1296MU2010 | 2010-04-20 | ||
| IN1296/MUM/2010 | 2010-04-20 | ||
| PCT/GB2011/000620 WO2011131943A2 (en) | 2010-04-20 | 2011-04-20 | Pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012149115A true RU2012149115A (ru) | 2014-05-27 |
Family
ID=44625957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012149115/15A RU2012149115A (ru) | 2010-04-20 | 2011-04-20 | Фармацевтическая композиция |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20130302415A1 (https=) |
| EP (1) | EP2560617A2 (https=) |
| JP (1) | JP2013525337A (https=) |
| KR (1) | KR20130076818A (https=) |
| CN (1) | CN102985072A (https=) |
| AU (1) | AU2011244783B2 (https=) |
| BR (1) | BR112012026843A2 (https=) |
| CA (1) | CA2796494A1 (https=) |
| GT (1) | GT201200284A (https=) |
| NZ (1) | NZ602955A (https=) |
| RU (1) | RU2012149115A (https=) |
| WO (1) | WO2011131943A2 (https=) |
| ZA (1) | ZA201207670B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201115633D0 (en) | 2011-09-09 | 2011-10-26 | Univ Liverpool | Compositions of efavirenz |
| US10646452B2 (en) * | 2013-03-15 | 2020-05-12 | New Jersey Institute Of Technology | System and method for fabrication of uniform polymer films containing nano and micro particles via continuous drying process |
| IN2013MU03370A (https=) | 2013-10-25 | 2015-09-25 | Cipla Ltd | |
| WO2015071841A1 (en) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| IN2014MU00916A (https=) * | 2014-03-20 | 2015-09-25 | Cipla Ltd | |
| CN104224790A (zh) * | 2014-09-28 | 2014-12-24 | 苏州普罗达生物科技有限公司 | 一种依法韦仑组合物及其制备方法 |
| PE20180690A1 (es) | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
| GB201515387D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| GB201515391D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| US11654112B2 (en) | 2016-11-22 | 2023-05-23 | Elektrofi, Inc. | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof |
| AU2018306303A1 (en) * | 2017-07-25 | 2020-02-20 | Elektrofi, Inc. | Formation of particles including agents |
| US20230040901A1 (en) * | 2018-01-04 | 2023-02-09 | PlantTec Medical GmbH | Pharmaceutical composition for inhibiting postoperative adhesions |
| ES2732498B2 (es) * | 2018-05-21 | 2020-04-27 | Consejo Superior Investigacion | Uso de efavirenz para el tratamiento de enfermedades de almacenamiento lipidico. |
| WO2019226969A1 (en) | 2018-05-24 | 2019-11-28 | Elektrofi, Inc. | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof |
| JP7522655B2 (ja) * | 2018-06-11 | 2024-07-25 | 大塚製薬株式会社 | デラマニド含有組成物 |
| EP3917500A2 (en) | 2019-01-31 | 2021-12-08 | Elektrofi, Inc. | Particle formation and morphology |
| WO2021050953A1 (en) | 2019-09-13 | 2021-03-18 | Elektrofi, Inc. | Compositions and methods for the delivery of therapeutic biologics for treatment of disease |
| AU2020395495B2 (en) * | 2019-12-02 | 2024-05-09 | Astrazeneca Ab | Solid pharmaceutical formulations of 6-(2-chloro-6-methylpyridin-4-yl)-5-(-4-fluorophenyl)-1,2,4-triazin-3-amine |
| JP2023522627A (ja) | 2020-04-17 | 2023-05-31 | エレクトロフィ，インコーポレイテッド | 連続的な液滴形成及び脱水によって粒子を形成する方法 |
| US20210330683A1 (en) * | 2020-04-20 | 2021-10-28 | Poviva Corp. | Compositions and methods for enhanced delivery of antiviral agents |
| CN112245400B (zh) * | 2020-11-10 | 2023-01-20 | 蓝龙药业(北京)有限公司 | 一种依法韦仑微片剂、制备方法及其应用 |
| CN114404377B (zh) * | 2022-01-10 | 2023-07-25 | 安徽贝克生物制药有限公司 | 一种阿巴卡韦、拉米夫定、依非韦伦复方片及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA72207C2 (uk) * | 1998-04-07 | 2005-02-15 | Брістол- Майєрс Сквібб Фарма Компані | Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення |
| EP1332757B1 (en) * | 1998-05-27 | 2012-06-13 | Merck Sharp & Dohme Corp. | Efavirenz compressed tablet formulation |
| CO5070643A1 (es) | 1998-05-27 | 2001-08-28 | Merck & Co Inc | Formulacion en tabletas comprimidas |
| US20030124186A1 (en) * | 2001-11-27 | 2003-07-03 | Hussain Munir A. | Efavirenz tablet formulation having unique biopharmaceutical characteristics |
| PE20070188A1 (es) * | 2005-06-29 | 2007-03-16 | Wyeth Corp | Formulaciones de estrogenos conjugados y bazedoxifeno |
| US20080026062A1 (en) * | 2006-07-31 | 2008-01-31 | Isaac Farr | Pharmaceutical compositions including nano-sized active agent |
| TWI405590B (zh) * | 2007-04-06 | 2013-08-21 | 活效製藥股份有限公司 | 微粉碎化有機化合物粒子之製法 |
| US20090088424A1 (en) * | 2007-08-17 | 2009-04-02 | Ilan Zalit | Methods and compositions for controlling the bioavailability of poorly soluble drugs |
| JP4606444B2 (ja) * | 2007-08-21 | 2011-01-05 | アピ株式会社 | アントシアニン含有経口投与用組成物及びその製造方法 |
| WO2010068899A1 (en) * | 2008-12-12 | 2010-06-17 | Creighton University | Nanoparticles comprising combinations of antiretroviral agents and use thereof |
| US10952965B2 (en) * | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
| GB201006038D0 (en) * | 2010-04-12 | 2010-05-26 | Unilever Plc | Improvements relating to antiviral compositions |
-
2011
- 2011-04-20 WO PCT/GB2011/000620 patent/WO2011131943A2/en not_active Ceased
- 2011-04-20 AU AU2011244783A patent/AU2011244783B2/en not_active Ceased
- 2011-04-20 CN CN2011800201397A patent/CN102985072A/zh active Pending
- 2011-04-20 KR KR1020127030186A patent/KR20130076818A/ko not_active Ceased
- 2011-04-20 NZ NZ602955A patent/NZ602955A/en not_active IP Right Cessation
- 2011-04-20 EP EP11716002A patent/EP2560617A2/en not_active Withdrawn
- 2011-04-20 JP JP2013505533A patent/JP2013525337A/ja active Pending
- 2011-04-20 CA CA2796494A patent/CA2796494A1/en not_active Abandoned
- 2011-04-20 BR BR112012026843A patent/BR112012026843A2/pt not_active IP Right Cessation
- 2011-04-20 RU RU2012149115/15A patent/RU2012149115A/ru not_active Application Discontinuation
-
2012
- 2012-10-12 ZA ZA2012/07670A patent/ZA201207670B/en unknown
- 2012-10-18 GT GT201200284A patent/GT201200284A/es unknown
-
2013
- 2013-07-14 US US13/941,525 patent/US20130302415A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2560617A2 (en) | 2013-02-27 |
| AU2011244783A1 (en) | 2012-11-01 |
| ZA201207670B (en) | 2013-05-29 |
| WO2011131943A8 (en) | 2012-11-29 |
| KR20130076818A (ko) | 2013-07-08 |
| CA2796494A1 (en) | 2011-10-27 |
| US20130302415A1 (en) | 2013-11-14 |
| GT201200284A (es) | 2014-08-26 |
| AU2011244783B2 (en) | 2015-11-12 |
| JP2013525337A (ja) | 2013-06-20 |
| WO2011131943A3 (en) | 2011-12-29 |
| BR112012026843A2 (pt) | 2016-07-12 |
| CN102985072A (zh) | 2013-03-20 |
| NZ602955A (en) | 2015-02-27 |
| WO2011131943A2 (en) | 2011-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012149115A (ru) | Фармацевтическая композиция | |
| JP2013525337A5 (https=) | ||
| AU2011309872B2 (en) | Pharmaceutical composition comprising deferasirox | |
| RU2013113752A (ru) | Фармацевтическая композиция | |
| US9867801B2 (en) | Amorphous solid dispersion comprising taxane, tablet comprising the same, and method for preparing the same | |
| CN104288154B (zh) | 一种含有不同粒径范围的法匹拉韦药物组合物 | |
| RU2015128609A (ru) | Перенасыщенные стабилизированные наночастицы для слаборастворимых лекарственных средств | |
| ES2437072T5 (es) | Preparación sólida | |
| CN105982870B (zh) | 一种阿哌沙班片剂 | |
| CN104902905A (zh) | 药物组合物 | |
| US20130004550A1 (en) | Sustained-release solid preparation for oral use | |
| CN103006661B (zh) | 一种含有盐酸鲁拉西酮的制剂及其制备方法 | |
| CN103705520A (zh) | 一种利伐沙班固体组合物的制备方法 | |
| CA2439097C (en) | Pharmaceutical compositions | |
| CN104666262B (zh) | 一种利伐沙班片 | |
| CN101862325B (zh) | 一种含有坎地沙坦酯的药物组合物 | |
| CN104666260B (zh) | 一种依折麦布片剂 | |
| CN104606139A (zh) | 一种药物粉末的制备与应用 | |
| CN103006602B (zh) | 一种快速溶出的阿托伐他汀钙片及其制备方法 | |
| Semalty | Preparation and evaluation of chitosan microsphere of metformin hydrochloride and to study the effect of drug to polymer ratio | |
| CN102895185B (zh) | 一种联苯双酯速释微丸及其制备方法和应用 | |
| CN102688216A (zh) | 一种加巴喷丁片剂及其制备方法 | |
| WO2018130943A1 (en) | Oral pharmaceutical composition of lurasidone and preparation thereof | |
| BR102012027409A2 (pt) | composição farmacêutica e seu método de preparo | |
| OA16372A (en) | Reclaimer machine. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160825 |